
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
In this video, Naeem Bhojani, MD, FRCSC, and David-Dan Nguyen discuss the patient selection, learning curve and takeaways of the study, “WATER vs WATER II: Three Year Comparison of Aquablation Therapy for Benign Prostatic Hyperplasia,” presented at the 2021 American Urological Association Annual Meeting. Bhojani is a urologist at CHUM Research Centre and an associate professor in the departments of surgery and social and preventative medicine at the University of Montreal, and Nguyen is a medical student at McGill University, Montreal, Quebec, Canada.